Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HCM NASDAQ:NAMS NASDAQ:QURE NASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$15.95-0.3%$16.60$11.51▼$21.50$2.78B0.4578,731 shs10,634 shsNAMSNewAmsterdam Pharma$26.66-0.1%$24.32$14.06▼$27.35$3.00B-0.01886,268 shs319,391 shsQUREuniQure$46.92+243.5%$15.24$4.45▼$51.21$2.59B0.141.71 million shs65.95 million shsSRRKScholar Rock$33.91+0.5%$34.47$6.76▼$46.98$3.25B0.361.39 million shs1.74 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED-4.02%-8.31%-0.68%+3.29%-3.09%NAMSNewAmsterdam Pharma-1.40%+8.77%+6.68%+45.50%+72.40%QUREuniQure-1.23%-5.60%-12.99%-4.68%+170.50%SRRKScholar Rock+3.59%+4.36%-4.90%-5.75%+289.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$15.95-0.3%$16.60$11.51▼$21.50$2.78B0.4578,731 shs10,634 shsNAMSNewAmsterdam Pharma$26.66-0.1%$24.32$14.06▼$27.35$3.00B-0.01886,268 shs319,391 shsQUREuniQure$46.92+243.5%$15.24$4.45▼$51.21$2.59B0.141.71 million shs65.95 million shsSRRKScholar Rock$33.91+0.5%$34.47$6.76▼$46.98$3.25B0.361.39 million shs1.74 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED-4.02%-8.31%-0.68%+3.29%-3.09%NAMSNewAmsterdam Pharma-1.40%+8.77%+6.68%+45.50%+72.40%QUREuniQure-1.23%-5.60%-12.99%-4.68%+170.50%SRRKScholar Rock+3.59%+4.36%-4.90%-5.75%+289.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCMHUTCHMED 2.00Hold$20.8830.35% UpsideNAMSNewAmsterdam Pharma 2.89Moderate Buy$42.0055.30% UpsideQUREuniQure 3.00Buy$37.45-23.04% DownsideSRRKScholar Rock 3.23Buy$46.4038.14% UpsideCurrent Analyst Ratings BreakdownLatest QURE, NAMS, HCM, and SRRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/24/2025SRRKScholar RockPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$52.00 ➝ $51.009/24/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.009/24/2025SRRKScholar RockBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$45.00 ➝ $44.009/23/2025SRRKScholar RockHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $44.009/22/2025HCMHUTCHMEDMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeEqual Weight ➝ Underweight$18.00 ➝ $13.759/17/2025SRRKScholar RockBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$45.009/16/2025SRRKScholar RockBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$45.009/15/2025SRRKScholar RockLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/15/2025SRRKScholar RockLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$51.009/9/2025HCMHUTCHMEDZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/8/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.00(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCMHUTCHMED$630.20M4.43$0.28 per share58.00$4.43 per share3.62NAMSNewAmsterdam Pharma$64.01M47.59N/AN/A$8.20 per share3.30QUREuniQure$27.12M98.47N/AN/A($0.14) per share-347.64SRRKScholar Rock$33.19M97.29N/AN/A$3.94 per share8.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCMHUTCHMED$37.73MN/A0.0010.97N/AN/AN/AN/AN/ANAMSNewAmsterdam Pharma-$241.60M-$1.62N/AN/AN/A-259.07%-27.27%-25.00%11/5/2025 (Estimated)QUREuniQure-$239.56M-$3.92N/AN/AN/A-1,387.98%-1,010.74%-33.27%11/4/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%11/11/2025 (Estimated)Latest QURE, NAMS, HCM, and SRRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025NAMSNewAmsterdam Pharma-$0.52-$0.15+$0.37-$0.15$1.44 million$19.15 million8/6/2025Q2 2025SRRKScholar Rock-$0.66-$0.98-$0.32-$0.98$0.11 millionN/A7/29/2025Q2 2025QUREuniQure-$0.89-$0.69+$0.20-$0.69$5.00 million$5.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHCMHUTCHMEDN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCMHUTCHMED0.054.654.51NAMSNewAmsterdam PharmaN/A21.0821.08QUREuniQure1.539.989.98SRRKScholar Rock0.216.336.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCMHUTCHMED8.82%NAMSNewAmsterdam Pharma89.89%QUREuniQure78.83%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipHCMHUTCHMED3.60%NAMSNewAmsterdam Pharma20.84%QUREuniQure4.79%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCMHUTCHMED1,811174.42 million168.14 millionNot OptionableNAMSNewAmsterdam Pharma4112.63 million89.16 millionOptionableQUREuniQure50054.87 million52.24 millionOptionableSRRKScholar Rock14096.13 million83.34 millionOptionableQURE, NAMS, HCM, and SRRK HeadlinesRecent News About These CompaniesScholar Rock (NASDAQ:SRRK) Price Target Lowered to $44.00 at BarclaysSeptember 24 at 8:46 AM | marketbeat.comScholar Rock (NASDAQ:SRRK) Given New $44.00 Price Target at HC WainwrightSeptember 24 at 2:38 AM | americanbankingnews.comScholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility IssuesSeptember 23 at 12:33 AM | msn.comScholar Rock stock falls after FDA issues response letter for SMA drugSeptember 23 at 7:28 PM | ca.investing.comFDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent ...September 23 at 7:28 PM | finance.yahoo.comUS FDA declines to approve Scholar Rock's muscle weakness drug; shares fallSeptember 23 at 7:28 PM | msn.comScholar Rock: Despite CRL, This Is A Strong Buy With Apitegromab ExpansionsSeptember 23 at 7:28 PM | seekingalpha.comScholar Rock (NASDAQ:SRRK) Shares Gap Down Following Analyst DowngradeSeptember 23 at 1:51 PM | marketbeat.comScholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana InspectionSeptember 23 at 11:32 AM | benzinga.comScholar Rock (NASDAQ:SRRK) Price Target Cut to $44.00 by Analysts at HC WainwrightSeptember 23 at 11:00 AM | marketbeat.comScholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA DrugSeptember 23 at 10:02 AM | investors.comFirefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionSeptember 23 at 8:16 AM | benzinga.comUS FDA declines to approve Scholar Rock's muscle weakness drugSeptember 23 at 7:12 AM | reuters.comScholar Rock (NASDAQ:SRRK) Stock Price Up 9% - Should You Buy?September 22 at 5:20 PM | marketbeat.comVoya Investment Management LLC Cuts Position in Scholar Rock Holding Corporation $SRRKSeptember 20, 2025 | marketbeat.comA Looming FDA Decision, Approval Odds, Investor TakeawaysSeptember 19, 2025 | forbes.comScholar Rock (NASDAQ:SRRK) Stock Rating Upgraded by BarclaysSeptember 19, 2025 | marketbeat.comBarclays Begins Coverage on Scholar Rock (NASDAQ:SRRK)September 19, 2025 | americanbankingnews.comBrokers Issue Forecasts for Scholar Rock Q3 EarningsSeptember 19, 2025 | americanbankingnews.comScholar Rock (NASDAQ:SRRK) Director Katie Peng Sells 1,006 SharesSeptember 18, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Insider Mo Qatanani Sells 3,178 SharesSeptember 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQURE, NAMS, HCM, and SRRK Company DescriptionsHUTCHMED NASDAQ:HCM$15.95 -0.04 (-0.25%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.NewAmsterdam Pharma NASDAQ:NAMS$26.66 -0.02 (-0.06%) As of 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.uniQure NASDAQ:QURE$46.92 +33.26 (+243.51%) As of 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Scholar Rock NASDAQ:SRRK$33.90 +0.16 (+0.46%) As of 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm’s RSI Just Hit Its High of the Year—Why That’s Bullish 2 Ways to Trade Amazon Ahead of October’s Prime Day AutoZone Pulls Into a Buy-the-Dip Opportunity Rocket Lab’s Bullish Case Remains Intact Despite Recent Offering Broadcom Price Targets Just Reached Above $400 for the First Time Replace Your Fixed Income With This Dividend ETF These 3 Mega-Cap Giants Just Increased Dividends by 7% or More 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
